Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > BUSINESS
BUSINESS
- Novartis Sales Reps Transferred Patient Questionnaires in Investigator-Led Trial
January 20, 2014
- Japan’s First SGLT-2 Inhibitor Suglat Approved: Astellas
January 20, 2014
- Otsuka Files Abilify Once-Monthly Injectable in Japan
January 17, 2014
- Alcon Japan Merges with CIBA Vision
January 17, 2014
- MTPC Files Telavic for Chronic Hepatitis C Genotype 2
January 17, 2014
- FDA Raises Concerns about Ranbaxy’s India Plant with Form 483
January 16, 2014
- Japan Added as Mogamulizumab PIII Study Site for CTCL Patients: Kyowa Kirin
January 16, 2014
- Takeda to Sell BIKEN Varicella Vaccine from February
January 16, 2014
- Swiss Novartis to “Fully Address” Flaws Leading to Criminal Complaint Filing
January 16, 2014
- Seikagaku Confirms Winning in Gel-One Patent Infringement Lawsuit Following Genzyme’s Withdrawal of Appeal
January 16, 2014
- Special Drug Use-Result Survey for Plavix Finds 0.19% Incidence of Cerebral Hemorrhage in Cerebral Infarction in Acute Phase
January 16, 2014
- Takeda Appoints Former GSK Exec as Head of CNS Drug Discovery Unit
January 15, 2014
- Shionogi Inc., Hisamitsu Unit to Copromote Hot Flashes Drug in US
January 15, 2014
- Daiichi Sankyo, 2 US Startups to Collaborate on Research of Academia-Oriented Seeds
January 14, 2014
- Ethical Drug Sales Up 0.8% in November Due to New Drug Launches and Lifting of 14-Day Prescription Limit: Crecon Report
January 14, 2014
- Pharma Biz Leaders Say New Price Cut Rule for Long-Listed Products a Painful Blow
January 10, 2014
- Daiichi Sankyo Submits NDA for Edoxaban in US
January 10, 2014
- Novartis Issues Apologies after Complaint Filing over Diovan, Vows Cooperation with Authorities
January 10, 2014
- Proposal to Reduce Basic Fees for Medical Institutions with Low Price Agreement Rates Could Have Big Impact: Mr Kono of Toho Pharmaceutical
January 10, 2014
- New IFN-Free Oral Drugs for Chronic Hepatitis C Could Create New Market
January 10, 2014
ページ
Japan’s pharmaceutical policy appears to be entering a new phase. The government’s newly approved honebuto policy and growth strategy both…
A few weeks ago, I had coffee with a very talented executive. Let’s call him Kenji. He has a great job, a big salary, and a solid team. But he was unhappy. He felt bored and wanted a new challenge.…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…